{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:26:14Z","timestamp":1793672774183,"version":"4.5.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.dmd.2026.100270","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:31:07Z","timestamp":1773041467000},"page":"100270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolism and excretion pathways of CD388, a novel drug-fragment crystallizable conjugate for prevention of seasonal or pandemic influenza"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3420-424X","authenticated-orcid":false,"given":"Jan","family":"Snoeys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4960-2811","authenticated-orcid":false,"given":"Grayson","family":"Hough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-6717","authenticated-orcid":false,"given":"Voon","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Rittase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1067-9374","authenticated-orcid":false,"given":"Tristan","family":"Baguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Carleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Breslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8621-3299","authenticated-orcid":false,"given":"Leslie W.","family":"Tari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.dmd.2026.100270_bib1","first-page":"1292","article-title":"Single-dose and repeat single-dose ascending dose study evaluating safety, tolerability, and pharmacokinetics of subcutaneous and intramuscular CD388, a novel long-acting drug-Fc conjugate for universal prevention of seasonal and pandemic influenza","volume":"12","author":"Flanagan","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.dmd.2026.100270_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmd.2026.100270_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cts.12697","article-title":"Population pharmacokinetic\/pharmacodynamic analysis of intravenous zanamivir in healthy adults and hospitalized adult and pediatric subjects with influenza","volume":"13","author":"Zuo","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"11","key":"10.1016\/j.dmd.2026.100270_bib4","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1128\/AAC.00703-11","article-title":"Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects","volume":"55","author":"Shelton","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.dmd.2026.100270_bib5","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41564-025-01955-3","article-title":"Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice","volume":"10","author":"D\u00f6hrmann","year":"2025","journal-title":"Nat Microbiol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100270_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2230618","article-title":"Therapeutic index improvement of antibody-drug conjugates","volume":"15","author":"Gerber","year":"2023","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.dmd.2026.100270_bib7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.dmd.2026.100270_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01059626","article-title":"Clearance concepts in pharmacokinetics","volume":"1","author":"Rowland","year":"1973","journal-title":"J Pharmacokinet Biopharm"},{"issue":"7","key":"10.1016\/j.dmd.2026.100270_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100103","article-title":"Absorption, distribution, metabolism, and excretion of an antiviral drug-Fc conjugate CD388 following subcutaneous administration of 14C-CD388 in the rat","volume":"53","author":"Laenen","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"33","key":"10.1016\/j.dmd.2026.100270_bib10","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall\u2019Acqua","year":"2006","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.dmd.2026.100270_bib11","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.158.5.2211","article-title":"Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1","volume":"158","author":"Medesan","year":"1997","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.dmd.2026.100270_bib12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int Immunol"},{"key":"10.1016\/j.dmd.2026.100270_bib13","series-title":"Safety testing of drug metabolites guidance for industry","year":"2020"},{"key":"10.1016\/j.dmd.2026.100270_bib14","series-title":"Clinical pharmacology considerations for antibody-drug conjugates guidance for industry","year":"2024"},{"issue":"6","key":"10.1016\/j.dmd.2026.100270_bib15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/19420862.2017.1337619","article-title":"Quantification of IgG monoclonal antibody clearance in tissues","volume":"9","author":"Eigenmann","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.dmd.2026.100270_bib16","article-title":"Pharmacokinetics in patients with impaired renal function \u2013 study design, data analysis, and impact on dosing","year":"2024","journal-title":"Guidance for industry"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:41:13Z","timestamp":1793670073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0090955626000395"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100270","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolism and excretion pathways of CD388, a novel drug-fragment crystallizable conjugate for prevention of seasonal or pandemic influenza","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100270"}}